Atara Biotherapeutics price target raised to $28 from $27 at H.C. Wainwright

H.C. Wainwright analyst Robert Burns raised the firm’s price target on Atara Biotherapeutics to $28 from $27 and keeps a Buy rating on the shares after the company presented updated results from the Phase 3 ALLELE trial, which evaluated tab-cel in Epstein-Barr virus-positive post-transplant lymphoproliferative disease. The analyst views the data as “encouraging.”